| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 1.428 | 718 | 577 | 611 | 700 | 390 | 627 | 1.017 | 1.779 | 896 |
| Total Income - EUR | 1.428 | 718 | 577 | 648 | 700 | 390 | 627 | 1.017 | 1.779 | 896 |
| Total Expenses - EUR | 1.178 | 769 | 320 | 622 | 483 | 375 | 1.523 | 3.746 | 1.070 | 339 |
| Gross Profit/Loss - EUR | 249 | -51 | 257 | 26 | 218 | 15 | -896 | -2.729 | 709 | 556 |
| Net Profit/Loss - EUR | 207 | -73 | 239 | 6 | 197 | 3 | -914 | -2.747 | 596 | 467 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
Check the financial reports for the company - Dotali-Improdex Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 4.283 | 240 | 496 | 542 | 836 | 1.000 | 954 | 721 | 153 | 600 |
| Inventories | 3.553 | 53 | 316 | 481 | 681 | 929 | 873 | 709 | 9 | 88 |
| Receivables | 647 | 3 | 10 | 52 | 41 | 62 | 32 | 0 | 0 | 0 |
| Cash | 84 | 184 | 170 | 9 | 115 | 9 | 48 | 12 | 144 | 512 |
| Shareholders Funds | -8.027 | -8.019 | -7.644 | -7.497 | -7.155 | -7.016 | -7.775 | -10.546 | -9.918 | -9.395 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 12.311 | 8.259 | 8.139 | 8.039 | 7.991 | 8.017 | 8.728 | 11.267 | 10.071 | 9.996 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "5211 - 5211" | |||||||||
| CAEN Financial Year |
4711
|
|||||||||
Comments - Dotali-Improdex Srl